Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
High-priority source disagreement: the old handbook supplies small doses in severe renal disease, while the later toxicity recommendation advises avoidance. No patient-specific safe dose is calculated.
Check source scope before reading a dose
Baclofen toxicity in kidney disease - author recommendations
Product / population
Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Renal method
eGFR, mL/min/1.73 m2
Source revision
2018; published online 2017
Retrieved
2026-09-05
Local review status
Separate professional-source protocol; not automatically equivalent to product labeling.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Older-adult avoidance guidance is more conservative than a generic reduction instruction
AGS 2023 recommends avoidance in older adults below its eGFR threshold, whereas the product-label summary advises caution and possible reduction.
What to reconcile: Review the age-specific source before using a reduced-dose schedule. The geriatric warning is not an intrathecal dosing rule.
Wolf et al. / American Journal of Kidney Diseases · Adults with spasticity; oral immediate-release baclofen only. Intrathecal doses and pump management are excluded. Severe kidney impairment is a high-risk toxicity setting.
Separate professional-source protocol; not automatically equivalent to product labeling.
Source-specific renal protocol
The authors recommend reducing baclofen exposure when eGFR is 30-60 mL/min/1.73 m2 and avoiding baclofen when eGFR is below 30 or the patient receives renal replacement therapy. This case-based recommendation does not supply a validated numeric reduced-dose schedule.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.